Nektar Therapeutics (NKTR) Total Current Liabilities (2010 - 2026)

Nektar Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $57.7 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 18.64% year-over-year to $57.7 million in Q1 2026; TTM through Mar 2026 was $57.7 million, a 18.64% decrease from a year earlier, with the FY2025 full-year figure at $53.5 million, down 12.81% from the prior year.
• Total Current Liabilities improved to $57.7 million in Q1 2026 per NKTR's latest filing, from $53.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $105.3 million in Q1 2022 and bottomed at $50.7 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $61.4 million (2024), against an average of $66.8 million.
• Across the five-year window, Total Current Liabilities slumped 51.71% in 2023 and soared 35.35% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $68.2 million in 2022, then declined by 24.83% to $51.3 million in 2023, then increased by 19.76% to $61.4 million in 2024, then dropped by 12.81% to $53.5 million in 2025, then rose by 7.79% to $57.7 million in 2026.
• Per Business Quant, the three latest NKTR Total Current Liabilities figures stand at $57.7 million (Q1 2026), $53.5 million (Q4 2025), and $66.3 million (Q3 2025).